FLAG-IDA May Induce Second Chronic Phase in Patients With Chronic Myeloid Leukemia
Researchers sought to determine whether treatment with FLAG-IDA could induce a second chronic phase in patients with CML.
Researchers sought to determine whether treatment with FLAG-IDA could induce a second chronic phase in patients with CML.
Researchers sought to determine whether asciminib would be better than bosutinib for treating patients with chronic myeloid leukemia in chronic phase.
Patients may not have much information on chronic myeloid leukemia, and some may have a number of misunderstandings surrounding the condition. As a health care professional, what are some of these myths you can correct to better educate patients?
Researchers sought to determine the accuracy of established cardiovascular assessment tools in predicting risk of CV events in patients with CML receiving TKIs.
Researchers sought to determine whether there was a difference in generic or branded imatinib in treating patients with CML.
Researchers evaluated the benefit-risk ratio across 3 ponatinib starting doses in patients with chronic phase chronic myeloid leukemia.
Tyrosine kinase inhibitors have improved survival outcomes for patients with CML, but these agents also have a greater risk for adverse cardiovascular events.
Among patients with CML, 32 were evaluable for ORR, which was determined to be 21.9%.
Researchers sought to determine the optimal benefit/risk profile for ponatinib in patients with resistant/intolerant chronic-phase chronic myeloid leukemia.
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.